ARTICLE | Company News
OncoSec, Serametrix Corp. deal
November 21, 2011 8:00 AM UTC
The companies will analyze patients from three ongoing Phase II trials of OncoSec's DNA IL-12 to identify biomarkers for those most likely to respond to treatment. The trials are evaluating the DNA p...